Streptococcus agalactiae in urinary tract infections

F. S. MHALU

Department of Bacteriology, Royal Postgraduate Medical School, Hammersmith Hospital, London W12

Summary
Streptococcus agalactiae was found to be the cause of approximately 1% of urinary tract infections in a London teaching hospital in the 2 years studied. Of the forty-eight patients with this infection, forty-three were female. In nine patients the infection followed renal transplantation while in nine others it occurred in the presence of chronic renal failure. The rest, who included seven females who developed the infection following hysterectomies, had other clinical conditions which could have predisposed to such infections. The rarity of urinary tract infection by S. agalactiae is in contrast to the high frequency with which the organism colonizes the normal urethra. Serotypes III and II were the predominant isolates in these patients with urinary tract infections; this corresponds to the distribution of the different serotypes in the genito-urinary tract of normal individuals.

Introduction
Streptococcus agalactiae (Lancefield’s group B Streptococcus) constitutes part of the normal bacterial flora of the human lower genito-urinary tract. Carriage rates in this site vary according to methods of detection used but values up to 36% have been reported from the more recent investigations (Christensen et al., 1976; Finch, French and Phillips, 1976). Although venereal transmission of the organism has been suggested, there is no evidence to support its role as a cause of primary genital pathology (Wallin and Forsgren, 1975). The major risk attaching to group B streptococci in the genital tract lies in their association with neonatal septicemia and meningitis (Baker and Barrett, 1973; Yow, 1974). Little work has been done on their relationship to urinary tract infections. Eickhoff et al. (1964) reported three female patients with acute pyelonephritis from two of whom 10⁸ colony-forming units of the organism/ml of urine were isolated. The third was diagnosed by isolation of the organism from blood culture. Wilkinson, Facklam and Wortham (1973) reported on 107 reference strains of group B streptococci from urinary tract infections but could not confirm an aetiological role for all the isolates because no quantitative bacteriological data had been provided. Other reports of group B streptococci in urinary tract infections include those by Feingold, Stagg and Kunz (1966), Anthony and Concepcion (1975) and Mhalu (1976) but to date, details of the types of patients with urinary infections with this organism have not been documented. The reported high prevalence of group B streptococci in the urethra especially in those with sexually transmitted diseases encouraged investigation into the frequency with which they cause urinary tract infections and the types of patient involved.

Materials and methods
In the period between July 1974 and June 1976, a record was kept of all significant isolations of group B streptococci from urine. The age, sex and contributory clinical condition of each patient were noted. These were compared with a 10% random sample of all patients, seen in this hospital in 1975, with urinary tract infection due to organisms other than group B streptococci. The criteria used for urinary tract infection were a pure bacterial growth of more than 10⁸ colony-forming units/ml of freshly voided midstream urine together with pyuria. The latter was defined as more than five pus cells per high power field on microscopy of the centrifuged deposit from 10 ml of urine resuspended in 0·5 ml. Culture was by streaking a 1/300 ml loopful of well mixed urine on a MacConkey agar; a growth of 300 colonies or more represented more than 10³ organisms/ml. Primary sensitivity tests with ampicillin 25 µg; trimethoprim 1·25 µg; sulphafurazole 500 µg and nalidixic acid 30 µg or nitrofurantoin 200 µg discs were done using the Stokes method (Stokes and Waterworth, 1972) whenever pus cells or organisms were evident in large numbers on microscopy. Throat and vaginal swabs were obtained from some of the patients for culture for group B streptococci. The streptococci were identified as belonging to Lancefield’s group B using the antigen extraction method of Rantz and Randall (1955). Serotyping of isolates from thirty-two of the patients was done at the Streptococcus Reference Laboratory, Central Public Health Laboratory, Colindale, London.
Results

During the 2-year period, seventy-five isolates of significant growth of *S. agalactiae* were obtained from forty-eight patients with urinary tract infections. This accounted for a 1% overall incidence of the group B *Streptococcus* in urinary tract infection. One patient had the organism isolated in significant numbers on eight separate occasions over a period of 4 months. Another had it isolated on four separate occasions in 1 year. It was possible to get more than one urine specimen from twenty-one of the patients before antibacterial treatment was instituted and significant isolates of group B streptococci were confirmed in all of them. All but five of the patients were adult females varying in age between 19 and 81 years. The rest were males including a prematurely born neonate whose mother's vagina was colonized by group B *Streptococcus*. The primary clinical conditions of the forty-eight patients subsequently proved to have urinary tract infection with *S. agalactiae* are shown in Table 1, while the clinical conditions of those with urinary tract infection due to other organisms are shown in Table 2.

All the isolates grew optimally on MacConkey agar with pale pink colonies in most cases. Occasional isolates gave obvious pink lactose fermenting colonies but these were easily distinguishable from the small magenta colonies typical of *S. faecalis*. *S. agalactiae* could further be distinguished from *S. faecalis* on the primary sensitivity plates by being fully sensitive to sulpha furazole while *S. faecalis* is invariably resistant. All the isolates were sensitive to penicillin (ampicillin) and trimethoprim but, as expected, none was sensitive to nalidixic acid. The few strains which were tested against nitrofurantoin proved sensitive to it. Of the five female patients who had high vaginal swabs taken in addition to urine culture, four had identical *S. agalactiae* isolates. One patient who had urinary tract infection due to the *Streptococcus* 1 month before labour, had identical strains of the organism isolated from her throat and vaginal swabs and from various sites on her otherwise normal newborn infant.

Serotyping results shown in Table 3 indicated that type III constituted the majority of the isolates, followed by type II. The different serotypes were widely distributed among the clinical conditions and

### Table 1. Associated clinical conditions of patients with urinary tract infections due to *S. agalactiae*

<table>
<thead>
<tr>
<th>Clinical condition</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female</td>
</tr>
<tr>
<td>Post-renal transplant</td>
<td>8</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>8</td>
</tr>
<tr>
<td>Post-hysterectomy</td>
<td>7</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>4</td>
</tr>
<tr>
<td>Cystic kidneys</td>
<td>3</td>
</tr>
<tr>
<td>Normal young women (sexually active age)</td>
<td>3</td>
</tr>
<tr>
<td>Disease not directly related to urinary tract pathology, e.g. congestive heart failure</td>
<td>3</td>
</tr>
<tr>
<td>Urinary obstruction</td>
<td>2</td>
</tr>
<tr>
<td>Recurrent urinary tract infection</td>
<td>1</td>
</tr>
<tr>
<td>Fracture of femur in elderly woman</td>
<td>1</td>
</tr>
<tr>
<td>Puerperal pyrexia</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1</td>
</tr>
<tr>
<td>Post-transurethral prostatectomy</td>
<td>—</td>
</tr>
<tr>
<td>Hypertension with hemiplegia</td>
<td>1</td>
</tr>
<tr>
<td>Prematurity</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>43</td>
</tr>
</tbody>
</table>

### Table 2. Associated clinical conditions of a 10% random sample of patients with urinary tract infections due to organisms other than *S. agalactiae* in 1975

<table>
<thead>
<tr>
<th>Disease not directly related to urinary tract pathology, e.g. congestive cardiac failure</th>
<th>Sex</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Urethral catheter in situ</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Trauma to pelvis (including surgery to hip)</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Recurrent urinary tract infection</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>Normal young females (sexually active age)</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>No other condition</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Post-hysterectomy</td>
<td>6</td>
<td>—</td>
</tr>
<tr>
<td>Malignancy of a pelvic organ (including urinary bladder)</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Urine retention</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Indwelling catheter</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4</td>
<td>—</td>
</tr>
<tr>
<td>Haematuria</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Urinary incontinence</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Puerperal pyrexia</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Post-rental transplant</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Cystic kidneys</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>83</td>
<td>29</td>
</tr>
</tbody>
</table>

### Table 3. Serotypes of *S. agalactiae* from patients with urinary tract infections

<table>
<thead>
<tr>
<th>Serotypes</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>8</td>
</tr>
<tr>
<td>II</td>
<td>5</td>
</tr>
<tr>
<td>Ia</td>
<td>4</td>
</tr>
<tr>
<td>Ib</td>
<td>4</td>
</tr>
<tr>
<td>Ic</td>
<td>2</td>
</tr>
<tr>
<td>R</td>
<td>2</td>
</tr>
<tr>
<td>X</td>
<td>2</td>
</tr>
<tr>
<td>II/III</td>
<td>1</td>
</tr>
<tr>
<td>Non-tyachable</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>32</td>
</tr>
</tbody>
</table>
within the various units where these patients were nursed so that cross infection was unlikely.

Discussion

From the results, it is evident that despite its high prevalence in the urethra, S. agalactiae is a rare cause of urinary tract infection. Whereas colonization rates are highest in the urethra of individuals presenting with sexually-transmitted diseases (Christensen et al., 1974; Wallin and Forsgren, 1975), urinary tract infection by the organism occurs mostly in those with structural abnormalities in the urinary tract especially if associated with immunological deficiencies. Renal transplantation and chronic renal failure were the only significant predisposing clinical conditions to urinary tract infection with S. agalactiae as compared to predisposing conditions to urinary tract infection with other organisms (P<0.001 in each case).

Some of the patients had recurrence of infection even after adequate therapy with appropriate agents including ampicillin and co-trimoxazole to which all the isolates were fully sensitive. Recurrence may have been due to inadequate eradication of the organism from the reservoir of infection which includes the vagina and possibly faeces. The predominance of serotypes III and II of the organism in urinary tract infections in this study accords with the findings of Wilkinson et al. (1973) and of Anthony and Concepcion (1975). This relative prevalence of serotypes III and II also conforms to their prevalence in the genital tract of normal individuals (Finch et al., 1976; Anthony and Concepcion, 1975). This seems to indicate that the serotypes which manage to cause disease in the urinary tract do not have any special characteristics. They simply occur according to their predominance in colonizing the normal genital tract.

Acknowledgments

This work was done while the author was on a World Health Organization fellowship grant, but the statements made and the opinions expressed are not necessarily those of the WHO.

I am grateful to Dr J. H. Darrell for advice and to Dr M. T. Parker for agreeing to have the strains serotyped.

References


Streptococcus agalactiae in urinary tract infections.

F. S. Mhalu

*Postgrad Med J* 1977 53: 216-218
doi: 10.1136/pgmj.53.618.216

Updated information and services can be found at:
[http://pmj.bmj.com/content/53/618/216](http://pmj.bmj.com/content/53/618/216)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)